Actively Recruiting
Phase 2 Trial of Luspatercept Injection for Adults with Anemia Due to Chronic Kidney Disease
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-07-24
30
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating luspatercept to see if it can improve hemoglobin levels in adults with anemia caused by chronic kidney disease CKD. This study also aims to assess the safety of luspatercept by monitoring side effects in participants. The trial is a phase 2 treatment study sponsored by Memorial Sloan Kettering Cancer Center. Participants will receive luspatercept as a subcutaneous injection once every three weeks. The study does not include a comparison group and focuses on how luspatercept affects hemoglobin levels over time, particularly within 12 weeks and up to week 28. The treatment period is designed to test the effects and safety of the drug in this patient group. During the study, participants will have their hemoglobin levels closely monitored to measure improvements. Researchers will also evaluate other health indicators to ensure safety and effectiveness. The study involves regular visits for treatment and assessment, with the overall participation lasting up to the study completion date in July 2029.
CONDITIONS
Brief Title
A Study of Luspatercept in People With Anemia
Research Team
J
Jodi Mones, MD
J
Jeffrey Zwicker, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
